Want to get this daily news briefing by email? Here’s the sign-up.
WHAT WE’RE WATCHING
DEAL - Insys Therapeutics has agreed to pay $225 million to resolve civil and criminal actions brought by the DOJ over alleged kickbacks and marketing of its opioid painkiller, Amanda Bronstad reports. Under the deal, announced on Wednesday, Insys agreed to pay $195 million to settle allegations in five separate whistleblower lawsuits that it violated the False Claims Act. Its operating subsidiary also will plead guilty to five counts of mail fraud and pay a $2 million fine and $28 million in forfeiture.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
